Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV119 SAD and Food Effect Study in Healthy Volunteers
NCT06105151Phase 1Active, not recruiting
- Sponsor
- Vigonvita Life Sciences
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VV119 in schizophrenia (3 arms), sponsored by Vigonvita Life Sciences. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 56 days, Maximum Plasma Concentration at 480 hours and 11 more. Started Oct 2023; status: active, not recruiting.
02
Drugs
VV119
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06105151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06105151.